Jild 3 № 1 (2026): Yanvar - Mart
75-91
2026-03-30
Ochiq kirish

Lipidlar almashinuvi va gipolipidemik terapiyaning zamonaviy yondashuvlari

Malika U.Yaxyoeva
Rano B.Alieva
Aleksandr B.Shek
DOI: https://doi.org/10.70626/cardiouz-2026-3-00080

Qabul qilingan: 2026-06-17 08:40:21

Nashr etilgan: 2026-03-30

PDF (ruscha)
Crossmark Crossmark

Annotatsiya

Lipidlar almashinuvining buzilishi aterosklerotik yurak-qon tomir kasalliklari rivojlanishining yetakchi xavf omillaridan biri bo‘lib, bugungi kunda ham butun dunyoda miqyosida yuqori ahamiyatga ega. Past zichlikdagi lipoproteinlar xolesterini darajsini pasaytirish borasidagi sezilarli yutuqlarga qaramay, ko’plab bemorlarda triglitseridlarga boy lipoproteinlar, remnant xolesterin va Lp (a) bilan bog’liq qoldiq yurak-qon tomir xavfi saqlanib qolmoqda. Ushbu sharhda lipidlar almashinuvi zamonaviy jihatlari, jumladan, lipoproteinlar transportining ekzogen va endogen yo‘llari, shuningdek, gipolipidemik terapiyaning zamonaviy strategiyalari, xususan, PCSK9, ANGPTL3, ApoC III va LP (a) ga yo’naltirilgan preparatlar haqidagi ma’lumotlar ko‘rib chiqildi. Interferensiyalovchi RNKlar, antisens oligonukleotidlar va CRISP/Cas9 genomni tahrirlash texnologiyalariga asoslangan istiqbolli davolash usullariga alohida e’tibor qaratilgan. Tahlil qilingan ma’lumotlar lipid almashinuvi mexanizmlarini chuqurroq tushunish dislipidemiyalarni yanada samarali nazorat qilish va yurak-qon tomir asoratlari xavfini kamaytirishga qaratilgan innovatsion davolash usullarini ishlab chiqishga xizmat qilayotganini ko’rsatadi.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Clinical Protocols, Guidelines, and Recommendations of the Ministry of Health of the Republic of Uzbekistan, 2024. In Russian: Клинические протоколы, руководства, рекомендации Министерства здравоохранения Республики Узбекистан 2024. https://diseases.medelement.com/disease/BD-2024/18879.

  2. Cardiovascular Disease Incidence Rates by Country in 2026. (May 7, 2026). World Population Review. In Russian: Показатели заболеваемости сердечно-сосудистыми заболеваниями в странах в 2026 году. (07.05.2026). Обзор мирового населения. https://worldpopulationreview.com/country-rankings/heart-disease-rates-by-country.

  3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), https://doi.org/10.1093/eurheartj/ehz455.

  4. Anne-Marie K Jepsen, Anne Langsted, Anette Varbo, Lia E Bang, Pia R Kamstrup, Børge G Nordestgaard, Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease, Clinical Chemistry, Volume 62, Issue 4, 1 April 2016, Pages 593–604, https://doi.org/10.1373/clinchem.2015.253757.

  5. Barbieri, L., Tumminello, G., Fichtner, I. et al. PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?. Curr Atheroscler Rep 26, 589–602 (2024). https://doi.org/10.1007/s11883-024-01230-6.

  6. Blom, D. J., Marais, A. D., Raal, F. J. (2025). Homozygous Familial Hypercholesterolemia Treatment: New Developments. Current atherosclerosis reports, 27(1), 22. https://doi.org/10.1007/s11883-024-01269-5.

  7. Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., Mora, S., . . . Wilkins, J. T. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 87(19), 2624–2757. https://doi.org/10.1016/j.jacc.2025.11.016.

  8. Casula, M., Colpani, O., Xie, S., Catapano, A. L., Baragetti, A. (2021). HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. Cells, 10(8), 1869. https://doi.org/10.3390/cells10081869.

  9. Chen, J., Fang, Z., Luo, Q. et al. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids Health Dis 23, 14 (2024). https://doi.org/10.118 6/s12944-023-01993-y.

  10. Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., Kozlovski, P., Cao, H., Wang, J., Nissen, S. E. (2025). Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). American heart journal, 287, 1–9. https://doi.org/10.1016/j.ahj.2025.03.019.

  11. Chubykina U.V., Tyurina A.V., Ezhov M.V. The era of targeted therapy for hyperlipidemia. Russian Journal of Cardiology. 2024;29(8):6038. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6038.EDN: YYMUYK.

  12. Duan, Y., Gong, K., Xu, S. et al. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Sig Transduct Target Ther 7, 265 (2022). https://doi.org/10.1038/s4 1392-022-01125-5.

  13. Feingold, K. R. (2024). Introduction to Lipids and Lipoproteins. In K. R. Feingold (Eds.) et. al., Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/.

  14. Ginsberg, H. N., Packard, C. J., Chapman, M. J., Bore´n, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., Lewis, G. F., Lichtenstein, A. H., Moulin, P., Nordestgaard,

  15. B. G., Remaley, A. T., Staels, B., Stroes, E. S. G., Taskinen, M. R., Tokgo¨ zog˘ lu, L. S., Tybjaerg-Hansen, A., . . . Catapano, A. L. (2021). Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. European heart journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551.

  16. Gouni-Berthold, I., Schwarz, J., Berthold, H. K. (2023). Updates in Drug Treatment of Severe Hypertriglyceridemia. Current atherosclerosis reports, 25(10), 701–709. https://doi.org/10.1007/s1 1883-023-01140-z.

  17. Griffiths, W. J., Wang, Y. (2021). Sterols, Oxysterols, and Accessible Cholesterol: Signalling for Homeostasis, in Immunity and During Development. Frontiers in physiology, 12, 723224. https://doi.org/ 10.3389/fphys.2021.723224.

  18. Gugliucci A. (2023). Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux. Journal of clinical medicine, 12(13), 4399. https://doi.org/10.3390/jcm12134399.

  19. Izar, M. C., Fonseca, F. A. H. (2025). Novel Therapeutics for Familial Chylomicronemia Syndrome. Current atherosclerosis reports, 27(1), 51. https://doi.org/10.1007/s11883-025-01295-x.

  20. Katsiki, N., Vrablik, M., Banach, M., Gouni-Berthold, I. (2025). Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?. Pharmaceuticals (Basel, Switzerland), 18(5), 753. https://doi.org/10.3390/ph18050753.

  21. Kindel, T., Lee, D. M., Tso, P. (2010). The mechanism of the formation and secretion of chylomicrons. Atherosclerosis. Supplements, 11(1), 11–16. https://doi.org/10.1016/j.atherosclerosissup.2010.03.003.

  22. Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Echavarria Uceta, R., Guzman, E., Rallidis, L. S. (2023). Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a). International journal of molecular sciences, 24(17), 13622. https://doi.org/10.3 390/ijms241713622.

  23. Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., Rallidis, L. S. (2025). Novel RNA-Based Therapies in the Management of Dyslipidemias. International journal of molecular sciences, 26(3), 1026. https://doi.org/10.3390/ijms26031026.

  24. Kosmas, C. E., Rallidis, L. S., Hoursalas, I., Papakonstantinou, E. J., Kostara, C. E. (2026). Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. International journal of molecular sciences, 27(2), 921. https://doi.org/10.3390/ijms27020921.

  25. Kounatidis D, Vallianou NG, Poulaki A, Evangelopoulos A, Panagopoulos F, Stratigou T, Geladari E, Karampela I, Dalamaga M. ApoB100 and Atherosclerosis: What’s New in the 21st Century? Metabolites. 2024; 14(2):123. https://doi.org/10.3390/metabo14020123.

  26. Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., Nissen, S. E. (2025). Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. The New England journal of medicine, 393(21), 2119–2130. https://doi.org/10.1056/NEJMoa2511778.

  27. Laguna-Maldonado, K. D., Uribe-Ram´ırez, D., Va´zquez-Carrada, M., Matuz-Mares, D., Vilchis-Landeros, M. M. (2025). Dysfunction of the ABCA1 and ABCG1 Transporters and Their Impact on HDL Metabolism. Antioxidants (Basel, Switzerland), 14(11), 1362. https://doi.org/10.3390/antiox14111362.

  28. Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., Mora, S. (2017). Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. Journal of the American Heart Association, 6(7), e005549. https://doi.org/10.1161/JAHA.117.005549.

  29. Li, T., Yang, Y., Qi, H. et al. CRISPR/Cas9 therapeutics: progress and prospects. Sig Transduct Target Ther 8, 36 (2023). https://doi.org/10.1038/s41392-023-01309-7.

  30. Llop, D., Ray, K. K. (2026). Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3):lessons from a randomized, placebo-controlled, phase 2 trial. Cardiovascular research, 122(7), 797–800. https://doi.org/10.1093/cvr/cvag045.

  31. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., Tokgozoglu, L., . . . ESC Scientific Document Group (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455.

  32. Nicholls S. J. (2023). PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. Kardiologia polska, 81(2), 115–122. https://doi.org/10.33963/KP.a2023.0030.

  33. Nicholls S. J. (2024). Therapeutic Potential of Lipoprotein(a) Inhibitors. Drugs, 84(6), 637–643. https://doi.org/10.1007/s40265-024-02046-z.

  34. Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., Son, V., Gaudet, D. (2020). Evinacumab in Patients with Refractory Hypercholesterolemia. The New England journal of medicine, 383(24), 2307–2319. https://doi.org/10.1056/NEJMoa2031049.

  35. Shi, Q., Chen, J., Zou, X., Tang, X. (2022). Intracellular Cholesterol Synthesis and Transport. Frontiers in cell and developmental biology, 10, 819281. https://doi.org/10.3389/fcell.2022.819281.

  36. Vanuzzo, D. The epidemiological concept of residual risk. Intern Emerg Med 6 (Suppl 1), 45 (2011). https://doi.org/10.1007/s11739-011-0669-5.

  37. Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Marat Ezhov, Michel P. Hermans, Ramesh Chandra Pandey, Kausik K. Ray, Lale Tokgo¨ zoglu, Alberto Zambon, Jean-Pascal Berrou, Michel Farnier, Non HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook, Atherosclerosis, Volume 383, 2023, 117312, ISSN 0021-9150, https://doi.org/10.1016/j.atherosclerosis.2023.117312.

  38. Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., Crooke, S. T., Witztum, J. L., Stroes, E. S., Tsimikas, S. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet (London, England), 388(10057), 2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1.

  39. Sylv ers-Davie, K. L., Davies, B. S. J. (2021). Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. American journal of physiology. Endocrinology and metabolism, 321(4), E493–E508. https://doi.org/10.1152/ajpendo.00195.2021.

Mualliflar haqida

Malika U.Yaxyoeva
myakh39@outlook.com
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi
Rano B.Alieva
ranoalieva@mail.ru
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi
Aleksandr B.Shek
shek-999@mail.ru
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazi

Litsenziya

Mualliflik huquqi (c) 2026 М.У. Яхъёева, Р.Б. Алиева, А.Б. Шек (Автор)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Lipidlar almashinuvi va gipolipidemik terapiyaning zamonaviy yondashuvlari (M. Yaxyoeva, R. Alieva, & A. Shek, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(1), 75-91. https://doi.org/10.70626/cardiouz-2026-3-00080
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)